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Abstract
Iron regulatory proteins, IRP1 and IRP2, bind to mRNAs harboring iron responsive elements and control their expression.
IRPs may also perform additional functions. Thus, IRP1 exhibited apparent tumor suppressor properties in a tumor xenograft
model. Here we examined the effects of IRP2 in a similar setting. Human H1299 lung cancer cells or clones engineered for
tetracycline-inducible expression of wild type IRP2, or the deletion mutant IRP2D73 (lacking a specific insert of 73 amino
acids), were injected subcutaneously into nude mice. The induction of IRP2 profoundly stimulated the growth of tumor
xenografts, and this response was blunted by addition of tetracycline in the drinking water of the animals, to turnoff the
IRP2 transgene. Interestingly, IRP2D73 failed to promote tumor growth above control levels. As expected, xenografts
expressing the IRP2 transgene exhibited high levels of transferrin receptor 1 (TfR1); however, the expression of other known
IRP targets was not affected. Moreover, these xenografts manifested increased c-MYC levels and ERK1/2 phosphorylation. A
microarray analysis identified distinct gene expression patterns between control and tumors containing IRP2 or IRP1
transgenes. By contrast, gene expression profiles of control and IRP2D73-related tumors were more similar, consistently with
their growth phenotype. Collectively, these data demonstrate an apparent pro-oncogenic activity of IRP2 that depends on
its specific 73 amino acids insert, and provide further evidence for a link between IRPs and cancer biology.
Citation: Maffettone C, Chen G, Drozdov I, Ouzounis C, Pantopoulos K (2010) Tumorigenic Properties of Iron Regulatory Protein 2 (IRP2) Mediated by Its Specific
73-Amino Acids Insert. PLoS ONE 5(4): e10163. doi:10.1371/journal.pone.0010163
Editor: Michael Polymenis, Texas A&M University, United States of America
Received December 29, 2009; Accepted March 23, 2010; Published April 13, 2010
Copyright:  2010 Maffettone et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a grant from the Cancer Research Society Inc (http://src-crs.ca/main.php?lang=2). CM was a recipient of a Post-Doctoral
Research Fellowship (PDFR) from the Government of Canada (http://www.scholarships.gc.ca/PDRFNonCdn-BRPDEtr-Eng.aspx). ID holds a pre-doctoral fellowship
from the British Heart Foundation (BHF) Centre of Excellence, Cardiovascular Division, King’s College London. KP holds a Chercheur National senior career award
from the Fonds de la Recherche en Sante ´ du Quebe ´c (http://www.frsq.gouv.qc.ca/en/index.shtml). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: kostas.pantopoulos@mcgill.ca
¤ Current address: Department of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
Introduction
IRP1 and IRP2 are homologous cytoplasmic proteins that post-
transcriptionally regulate cellular iron metabolism [1,2,3]. In iron-
starved cells, both IRPs are activated for binding to iron responsive
elements (IREs) within the untranslated regions of several mRNAs
and thereby modulate their stability or translation. Among other
targets, IRPs control the expression of transferrin receptor 1
(TfR1) and ferritin, which are key proteins of cellular iron uptake
and storage, respectively. The binding of IRPs stabilizes TfR1
mRNA and inhibits translation of H- and L-ferritin mRNAs,
promoting homeostatic adaptation to iron deficiency. Likewise,
IRPs control the stability or translation of IRE-containing mRNA
isoforms of the iron transporters DMT1 [4] and ferroportin [5].
IRPs are ubiquitously expressed in mammalian tissues and
share at least some degree of functional redundancy. This is
evident from the early embryonic lethality at the blastocyst stage,
associated with the ablation of both IRP1 and IRP2 in mice [6].
Moreover, conditional disruption of both IRP1 and IRP2 in the
mouse intestine elicits severe fatal pathology in this organ [7]. On
the other hand, single IRP1-/- or IRP2-/- knockout mice are
viable [8,9,10,11]. Nevertheless, it appears that IRP2 has a more
dominant role in vivo, considering that IRP1-/- mice are healthy
[8], while IRP2-/- counterparts develop microcytic anemia [9,11]
and neurodegeneration [10]. In agreement with these findings,
silencing experiments in HeLa cells identified IRP2 as the major
regulator of TfR1 and ferritin mRNA expression, without,
however, excluding a contribution of IRP1 [12].
In iron-replete cells,IRP1assembles acubane [4Fe-4S] clusterand
acquires enzymatic function as cytosolic aconitase, at the expense of
its RNA-binding activity [1,2], while IRP2 undergoes ubiquitination
by the E3 ligase FBXL5 and degradation by the proteasome [13,14].
Conversely, iron starvation triggers a switch of IRP1 from cytosolic
aconitase to an IRE-binding protein by loss of its [4Fe-4S] cluster,
and promotes stabilization of IRP2 following degradation of FBXL5.
The iron-dependent [4Fe-4S] cluster switch of IRP1 readily occurs
under standard cell culture conditions with 21% oxygen, but appears
less efficient al lower (3%–6%) oxygen levels that likely reflect
physiological tissue oxygenation [15]. In line with this notion, IRP1 is
predominantly expressed as aconitase in animal tissues, and only a
small fraction is activated for IRE-binding in response to iron
deficiency [16]. These findings support the idea that in vivo, the
expression of major IRE-containing mRNAs, such as those encoding
TfR1 and ferritin, is primarily regulated by IRP2. IRP1 may serve as
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exert more specialized functions for the control of other IRE-
containing transcripts [17].
Considering that iron is essential for cell proliferation [18], we
previously hypothesized that manipulations in the IRE/IRP
system to misregulate iron homeostasis may affect tumor growth.
To address this, we utilized human H1299 lung cancer cells
engineered for tetracycline-inducible expression of an IRP1
transgene, and assessed their capacity to form tumor xenografts
in nude mice. We reported that the overexpression of IRP1 (either
wild type, or a mutant carrying a C437S substitution that has
constitutive IRE-binding activity) drastically inhibits the growth of
tumor xenografts, without grossly affecting their iron content [19].
Here, we examine the effects of IRP2 in this model. We show
that overexpression of IRP2 elicits an opposite phenotype and
profoundly stimulates tumor growth, even though both IRPs
appear to regulate IRE-containing mRNAs within the tumors in a
similar manner. In addition, we provide evidence that the tumor-
promoting activity of IRP2 requires its specific insert of 73 amino
acids. Finally, we identify distinct gene expression patterns
between control tumors and those overexpressing IRP2 or IRP1,
that may account for their differential growth phenotypes.
Results
Overexpression of IRP2 promotes the growth of tumor
xenografts in nude mice
To assess the role of IRP2 in tumorigenesis, we employed
H1299 lung cancer cells overexpressing the wild type form of the
protein (HIRP2wt) under the control of a tetracycline-inducible
promoter. IRP2-transfectants and control parent cells were
injected subcutaneously into the flanks of BALB/c (nu/nu) mice
to form solid tumor xenografts (Fig. 1A). Palpable tumors were
detectable within 3–4 weeks post injection, and their volume was
monitored over time during the exponential growth phase. We
noted that tumors derived from IRP2-overexpressing cells were
growing much faster compared to controls (Fig. 1B). All mice were
sacrificed 10 weeks post injection and the tumors were excised for
biochemical and histological analysis. Tumors derived from IRP2-
overexpressing cells were profoundly larger, with 5.4-fold higher
average mass (Fig. 1C) and 4.6-fold higher average volume
(Fig. 1D) compared to controls. These data are consistent with an
apparent pro-oncogenic activity of IRP2.
To exclude the possibility that the observed phenotype is due to a
possible clonal effect unrelated to IRP2, further BALB/c (nu/nu)
Figure 1. IRP2-dependent accelerated tumor growth, mediated by its specific 73 amino acids insert. BALB/c nude mice were injected
with parent H1299, HIRP2wt or HIRP2D73 cells and tumor xenografts were grown for 10 weeks and monitored over time. (A) Representative
anesthetized mice before sacrifice; tumor xenografts are shown by arrows. (B–D) Cumulative data from three independent experiments (n=9 mice
for each group) depicting kinetics on tumor xenograft growth (B), mass (C) and volume (D) of isolated tumor xenografts. Data are expressed as mean
6 SEM. * p,0.05, ** p,0.01 versus H1299 (Student’s t-test).
doi:10.1371/journal.pone.0010163.g001
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receiving tetracycline in their drinking water throughout the
experimental period,to turn off the expression of the IRP2transgene,
while the other half were allowed to overexpress IRP2 in the
xenograft, without antibiotic (Fig. 2A). The rate of tumor growth was
substantiallyreducedintetracycline-treatedmice(Fig.2B).Moreover,
the average mass and size of tumors from theseanimals were 2.1- and
2.4-fold smaller, respectively, as compared to untreated counterparts
(Figs. 2C–D). The expression of HA-tagged IRP2 was undetectable
by Western blot analysis of tumor extracts with a HA antibody
(Fig. 2E), confirming the efficient turnoff of the tetracycline promoter
with the antibiotic. The reversion of the tumor growth phenotype by
tetracycline validates the pro-oncogenic function of IRP2 in this
xenograft model.
The tumor-promoting activity of IRP2 requires its specific
73 amino acids insert
Mammalian IRP2 molecules contain a unique conserved insert
of 73 amino acids close to their N-termini, that is absent in IRP1.
The function of this sequence remains largely unknown. To better
understand the requirements for the apparent pro-oncogenic
activity of IRP2, we evaluated the performance of HIRP2D73 cells,
overexpressing the IRP2D73 deletion mutant, in the tumorigenicity
assay. These cells formed solid tumor xenografts in nude mice, that
Figure 2. Tetracycline-dependent repression of the IRP2 transgene abolishes accelerated tumor growth. A total of 6 BALB/c nude mice
were injected with HIRP2wt cells to form tumor xenografts. Half of the animals were receiving 2 mg/ml tetracycline in the drinking water throughout
the experimental period, starting 4 days before injection. (A) Representative anesthetized mice from the two groups before sacrifice (tumors shown
by arrows). (B) Kinetics on tumor xenograft growth. (C) Mass and (D) volume of isolated tumor xenografts. (E) Tumor tissue extracts were analyzed by
Western blotting with antibodies against HA, to detect expression of the IRP2 transgene, and b-actin, as loading control. Data are expressed as mean
6 SEM. * p,0.05, ** p,0.01 versus HIRP2wt (Student’s t-test).
doi:10.1371/journal.pone.0010163.g002
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parent H1299 cells. Thus, in contrast to wild type protein,
IRP2D73 failed to drastically stimulate tumor growth and increase
tumor mass and size (Fig. 1), suggesting that the 73 amino acids
insert of IRP2 is necessary for its apparent pro-oncogenic function.
Interestingly, this insert also accounts for differential anchorage-
independent growth characteristics between HIRP2wt and
HIRP2D73 cells in soft agar. Thus, the former give rise to fewer
but larger colonies compared to parent cells, while the latter form
a big number of smaller size colonies (Fig. S1). To address whether
the 73 amino acids insert of IRP2 suffices to elicit pro-oncogenic
responses in vivo, we employed HIRP2DD4 and HIRP2DD4/273d
cells for the tumorigenicity assay in nude mice. These cells express
an inactive truncated version of IRP2, lacking the entire C-
terminal domain 4, in the presence (IRP2DD4) or absence
(IRP2DD4/273d) of the 73 amino acids insert (Fig. S2, A–B). Both
cell types formed slow-growing tumor xenografts in nude mice
with an indistinguishable kinetic and macroscopic phenotype (Fig.
S2, C–E). We conclude that the 73 amino acids domain of IRP2 is
necessary but not sufficient to promote tumor xenograft growth in
nude mice.
Tumor histology
Histological sections of tumor xenografts were stained with
hematoxylin and eosin (Fig. 3). Control tumors (derived from
parent H1299 cells) contain a solid sheet of cells (Fig. 3, left),
throughout which vascular channels are visible. They appear to
have well-defined cytoplasmic boundaries, a variable amount of
eosinophilic cytoplasm and nuclei that are pleomorphic, with
about 2-fold anisokaryosis. Mitoses are in excess of 12 high-power
field. Tumors derived from HIRP2wt cells (Fig. 3, middle) are
characterized by ,50% of necrotic mass with mostly coagulative
necrosis, that forms irregularly shaped serpentine regions. At the
border between viable and necrotic tissue there is pyknosis and
nuclear fragmentation. The viable cells form a diffuse sheet
without architectural sophistication or differentiation and there is
no intervening stroma. No blood vessels are seen within this mass.
The cells have an abundance of eosinophilic cytoplasm that is
often finely vacuolated. Nuclei are very large with about 10-fold
anisokaryosis and mitoses are 3 per high-power field. Tumors
derived from HIRP2D73 cells (Fig. 3, right) exhibit ,20% of
necrotic mass with coagulative necrosis and nuclear fragmentation
at the border between viable and necrotic tissue. There are some
blood vessels present in this mass and only near the periphery.
Perl’s iron staining was negative for all xenografts.
Biochemical analysis of tumor xenografts and cell lines
Analysis of tumor extracts by Western blotting with a HA antibody
(Fig. 4A, top panel) demonstrates the continuous expression of wild
type or mutant IRP2 in the tumors derived from HIRP2wt or
HIRP2D73 cells, respectively. We noticed that IRP2D73 was expressed
at lower levels than IRP2wt (compare lanes 3–4 with 5–6). To
examine whether this could account for the striking differences in the
tumor growth phenotype (Fig. 1), we normalized the tumor volumes
to relative expression levels of wild type or mutant protein from all
available experimental data. The graph in Fig. S3A demonstrates
that the lack of pro-oncogenic activity of IRP2D73 is genuine and
unrelated to its relatively lower expression.
Tumor extracts containing either IRP2wt or IRP2D73 exhibited
high IRE-binding activity in an electrophoretic mobility shift assay
(EMSA) (Fig. 4B). Nonetheless, the expression of only wild type
but not mutant protein correlated with a significant 2-fold increase
in TfR1 mRNA levels (Fig. 4C), accompanied by ,1.6-fold higher
TfR1 protein content (Fig. 4A, second panel). Interestingly,
neither IRP2wt nor IRP2D73 affected the expression of ferritin,
ferroportin or DMT1 (Fig. 4A), by analogy to earlier observations
in IRP1 xenografts [19]. A cumulative quantification of Western
blots from all available experiments is depicted in Fig. S3B. As
expected, ferritin mRNA levels were similar in all tumors (Fig. 4D).
We also performed a biochemical analysis of cultured HIRP2wt
and HIRP2D73 cells, to explore whether the above findings in the
xenograft tissue are due to basic IRP2 overexpression at the
cellular level, or possibly reflect more complex responses within
the tumor microenvironment. Extracts of both HIRP2wt and
HIRP2D73 cells were highly active in IRE-binding (Fig. 5A), as
observed earlier [20]. By analogy to the data in Fig. 4, the
overexpression of wild type but not mutant IRP2 in cells correlated
with increased TfR1 mRNA (Fig. 5B) and protein levels (Fig. 5C),
Figure 3. Hematoxylin and eosin staining of tumor xenografts derived from H1299 (left), HIRP2wt (middle) or HIRP2D73 (right) cells
(406magnification). Mitoses are shown by arrows; colored insets indicate eosinophilic cytoplasm, blood vessels, necrosis, nuclear fragmentation,
or cytoplasm vacuolization.
doi:10.1371/journal.pone.0010163.g003
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mediated protection of TfR1 mRNA did not suffice to increase its
steady state levels to the same extent as a treatment with the iron
chelator desferrioxamine (DFO), which is also known to stimulate
TfR1 mRNA transcription [21]; similar results were obtained with
H1299 cells expressing IRP1C437S [21]. Surprisingly, neither wild
type, nor mutant IRP2 suppressed ferritin expression (Fig. 5E) and
synthesis (Fig. 5F) despite their capacity to bind to ferritin IRE, at
least in vitro (Fig. 5A). We conclude that the biochemical data in
the xenografts recapitulate IRE/IRP responses in the HIRP2wt
and HIRP2D73 cells.
Further biochemical analysis of the xenografts revealed a
consistent and statistically significant 2-fold increase of c-MYC
expression and ERK1/2 phosphorylation in tumors derived from
HIRP2wt cells (Figs. 6A and B). By contrast, IRP2D73-containing
tumors exhibited considerable variability in c-MYC levels and no
difference in ERK1/2 phosphorylation. Neither wild type nor
mutant IRP2 affected the expression of cell division cycle 14A
protein (CDC14A) or vascular endothelial growth factor (VEGF)
(Fig. 6C). The CDC14A transcript is a potential target of IRPs
[22] and VEGF is transcriptionally induced by hypoxia inducible
factors (HIF), which are also associated with the IRE/IRP
regulatory system [17,23].
Analysis of gene expression profiles in tumor xenografts
Duplicate RNA samples (each from different animal) isolated
from control, IRP2, IRP2D73 or IRP1 [19] tumors xenografts were
subjected to cDNA microarray analysis. An array quality control
assessment of sample reproducibility by pairwise PCC calculations
excluded the presence of outliers among experimental replicates.
The normalized dataset was further filtered by removing
transcripts with low intensity values and low across-sample
Figure 4. Effects of wild type or mutant IRP2 transgenes in the expression of known downstream targets within the tumor
xenograft. (A) Extracts from tumor tissue were analyzed by Western blotting with antibodies against HA, TfR1, ferritin, ferroportin, DMT1 and b-
actin. (B) Tumor extracts were analyzed for IRE-binding activity by EMSA with a
32P-labeled ferritin IRE probe. (C and D) Analysis of TfR1 and H-ferritin
mRNA expression by qPCR.
doi:10.1371/journal.pone.0010163.g004
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t-test was applied to identify differentially expressed genes between
‘‘IRP2 vs control’’, ‘‘IRP2 vs IRP1’’, and ‘‘IRP2 vs IRP2D73’’
tumor xenografts (Fig. 7A). Genes with p-value #0.05 were
considered significant. As expected, the expression of the TFRC
gene (encoding TfR1) was increased in IRP2- as compared to
control and IRP2D73-tumors (Fig. S4). ‘‘IRP2 vs control’’ had 2001
differentially expressed genes, ‘‘IRP2 vs IRP1’’: 2766, and ‘‘IRP2
vs IRP2D73’’: 2517 (Fig. 7B; a full list is provided in Table S2).
There were 178 genes common to all differentially expressed
groups. Differential expression was validated by qPCR in
randomly selected genes (listed on Table S1).
Figure 5. Effects of wild type or mutant IRP2 transgenes in the expression of known downstream targets in cultured H1299 cells.
Parent H1299, HIRP2wt and HIRP2D73 cells were grown for 3 days in the absence or presence of tetracycline; where indicated, the cells were treated
overnight with 100 mM of desferrioxamine (DFO) or hemin. (A) Cytoplasmatic extracts were analyzed by EMSA with a
32P-labeled ferritin IRE-probe. (B)
Analysis of TfR1 mRNA expression by qPCR. (C) Western blotting with antibodies against HA, TfR1 and b-actin. (D) The cells were metabolically labeled
with
35S-methionine/cysteine and the synthesis of TfR1 was assessed by quantitative immunoprecipitation. (E) Western blotting with antibodies
against HA, ferritin and b-actin. (F) The cells were untreated or pretreated for 4 h with 100 mM hemin and, subsequently, metabolically labeled with
35S-methionine/cysteine; the synthesis of ferritin was assessed by quantitative immunoprecipitation.
doi:10.1371/journal.pone.0010163.g005
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PCCs were calculated for all common 178 genes across the
dataset. Pairwise gene co-expressions were used to construct an
undirected unweighted network such that genes are represented by
nodes and co-expression with PCC$0.90 by edges. The final
network consisted of 156 genes (Table S3) and 546 co-expressions.
22 genes were not strongly correlated and were excluded from the
network. MCL algorithm, an efficient, unsupervised, and accurate
graph clustering approach based on graph flow simulation [24],
was applied to group genes that may share a common biological
function. This approach identified 4 clusters with more than 10
genes (Fig. 7C). The largest cluster contained 63 genes (Table S3).
Further analysis of each MCL cluster for overrepresented GO-
BP terms uncovers that IRP1 and IRP2 elicit substantially distinct
downstream responses. Moreover, the overexpression of IRP2, but
not of IRP2D73, promotes differential expression of a wide range of
Figure 6. Tumor xenografts derived from HIRP2wt cells display an increase of c-MYC expression and ERK1/2 phosphorylation.
Extracts from tumor tissue were analyzed by Western blotting with antibodies against c-MYC, phospho-ERK1/2, ERK1/2, CDC14A, VEGF and b-actin.
Representative immunoblots and quantification from three independent experiments (n=9 mice)of (A) c-MYC, relative to b-actin; (B) phospho-ERK1/
2, relative to ERK 1/2; (C) CDC14A and VEGF, relative to b-actin. Data are expressed as means of relative band intensity 6 SEM. * p,0.05 versus H1299
(Student’s t-test).
doi:10.1371/journal.pone.0010163.g006
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regulation and G-protein coupled receptor signaling, but also in
metabolic processes, cell adhesion and growth (Fig. S5). Principal
component analysis demonstrates that gene expression profiles
between control and IRP2D73-expressing tumors exhibit remark-
able similarities (Fig. S6), consistently with their growth and
biochemical phenotypes.
Discussion
Prompted by the inhibitory effects of IRP1 in tumor xenograft
growth in nude mice [19], we examined the role of IRP2 in this
setting. The data in Fig. 1 show that IRP2 triggers opposite
responses and profoundly promotes tumor growth. Importantly, a
causal relationship is established by the reversion of this phenotype
with tetracycline, that efficiently turns off the expression of the
IRP2 transgene in vivo (Fig. 2). Even though the administration of
tetracycline clearly inhibited the pro-oncogenic function of IRP2,
the respective tumors were not growing as slow as controls
(compare Figs. 1 and 2). These small differences may be related to
experimental variability and/or minimal leakiness of the tetracy-
cline promoter (undetectable by immunoblotting).
In contrast to the wild type protein, the deletion mutant
IRP2D73 that lacks an IRP2-specific insert of 73 amino acids, failed
to stimulate tumor growth in the xenograft model (Fig. 1). Analysis
of the ratios of tumor volumes to the expression of HA-tagged
IRP2wt and IRP2D73 (Fig. S3A) excludes the possibility that this is
due to the relatively reduced expression of the mutant in tumors.
The IRP2-specific insert appears to be unstructured [25] and,
contrary to earlier assumptions, is dispensable for iron-dependent
degradation of the protein [13,14,20,26]. Our data provide strong
evidence that the 73 amino acids insert confers an apparent pro-
oncogenic activity to IRP2, and assign for the first time a
functional role for this unique sequence. The differential
anchorage-independent growth phenotypes of H1299 cells ex-
pressing either IRP2D73 or IRP2wt (Fig. S1) also imply a functional
significance of this sequence in cell proliferation. Nevertheless, the
73 amino acids insert failed to accelerate tumor xenograft growth
when expressed outside the context of full-length and functional
IRP2 (Fig. S2). Thus, the 73 amino acids insert is necessary but not
sufficient to elicit pro-oncogenic responses in vivo.
Tumors derived from IRP2-overexpressing cells, as well as these
cells in culture, maintained high levels of IRP2 at the experimental
endpoint and exhibited an upregulation of TfR1 mRNA and
protein (Figs. 4 and 5), in line with the function of IRP2 as
stabilizer of TfR1 mRNA. Interestingly, while IRP2D73 was
likewise highly expressed, it failed to upregulate TfR1. Consider-
ing that this deletion mutant exhibits IRE-binding activity in vitro
with a ferritin IRE-probe (Figs. 4 and 5), we speculate that it may
bind with reduced affinity to TfR1 IREs in vivo.
Surprisingly,thepresenceoftheIRP2wt (or IRP2D73)t r a n s g e n ed i d
not affect the expression of ferritin neither in xenografts, nor in
cultured cells (Figs. 4 and 5), even though IRPs are well-established
inhibitors of ferritin mRNA translation. Since the tumor xenografts
Figure 7. Analysis of gene expression profiles in tumor xenografts with altered expression of IRPs. (A) Hierarchical clustering of all
differentially expressed genes. Red and green colors represent up- and down-regulation. (B) Venn diagram of all differentially expressed genes. (C)
Co-expression network of 178 genes shared by all differential groups. Each gene is represented by a node and a Pearson correlation coefficient above
0.90 between any pair of genes is represented by an edge. Genes are colorized according to their distinct MCL cluster which may reflect a shared
biological function.
doi:10.1371/journal.pone.0010163.g007
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repressor activity of IRP2 is masked by high ferritin levels in stroma
cells. In addition, no IRP2-dependent alteration in ferritin mRNA
levels was observed, that could antagonize and mitigate the expected
translational repression. Similar unexpected findings were previously
documented in tumor xenografts overexpressing IRP1 [19], while the
overexpression of IRP1 only conditionally suppressed ferritin mRNA
translation in cultured H1299 cells grown at low densities [21]. We
previously reported that at higher cell densities, ferritin mRNA
bypassed the inhibitory activity of tetracycline-inducible IRP1 and
was efficiently translated [21]. Analogous results were obtained with
tetracycline-inducible IRP2, when HIRP2wt cells were freshly
generated (Guohua Chen and Kostas Pantopoulos, unpublished
observations). However, after several years of maintenance of the cell
lines in the lab, we are unable to observe any repression of ferritin
synthesis by IRP2 (or IRP1) at low cell densities (Fig. 5). We suspect
that the cells have adapted to the presence of exogenous IRP2 (or
IRP1), even under suppressive conditions with tetracycline, presum-
ably due to low leakiness of the tetracycline promoter.
The data in Fig. 6 indicate that within the tumor xenograft,
IRP2 (or IRP2D73) may also fail to control the expression of other
IRE-containing mRNAs, such as those encoding DMT1, ferro-
portin and CDC14A. Nevertheless, we cannot exclude the
possibility that all these proteins are encoded by non-IRE-
containing mRNA isoforms, generated by alternative splicing
[4,5,22]. The absence of any IRP2-dependent alterations in
VEGF levels may suggest that the H1299 cells primarily express
HIF-1a, that is unresponsive to IRPs. In any case, this finding is
concordant to the lack of vascularization in the necrotic tumor
mass (Fig. 3).
We noted that the expression of the IRP2 transgene in tumor
xenografts was associated with increased levels of the c-MYC
oncogene, as well as with increased ERK1/2 phosphorylation
(Figs. 6A and B). This was not the case with IRP2D73, even though
a trend towards higher c-MYC content was evident in IRP2D73-
related tumors, without reaching statistical significance. The
expression of c-MYC is regulated at multiple levels and
deregulation of this gene is associated with malignant transforma-
tion and cancer [27]. Our cDNA microarray analysis did not show
any increase in c-MYC mRNA levels. Thus, we speculate that the
IRP2-dependent increase in c-MYC protein content may be
related, at least partially, with stabilization of this protein following
phosphorylation by ERK1/2 [28].
The IRP2-dependent increase in c-MYC levels deserves
particular attention, considering that IRP2 is a direct transcrip-
tional target of c-MYC [29]. Our data are consistent with a
regulatory feedback loop between c-MYC and IRP2 that controls
tumor growth. It was proposed that the c-MYC-mediated
transcriptional activation of IRP2, and concomitant transcription-
al and translational suppression of H-ferritin by c-MYC and IRP2,
respectively, contribute to cell transformation by increasing the
intracellular iron pool [29]. In the tumor xenograft model
presented here, the pro-oncogenic properties of IRP2 are
independent of its capacity to regulate ferritin expression and
tumor iron levels. In line with this notion, the tumor suppressor
phenotype associated with IRP1 overexpression in tumor
xenografts was also independent of ferritin and iron levels [19].
Taken together, our data provide strong evidence that the
apparent pro-oncogenic activity of IRP2 is unrelated to the
established function of this protein as regulator of several known
IRE-containing mRNAs. The cDNA microarray analysis (Fig. 7)
demonstrates that the overexpression of either IRP2 or IRP1
transgenes is associated with distinct gene expression patterns in
tumors, that may account for their strikingly opposite growth
phenotypes. Furthermore, our data suggest that the unique 73
amino acids insert confers to IRP2 pro-oncogenic potential and is
essential for accelerated tumor growth. This view is reinforced by
the microarray results, that uncover considerable similarities in
gene expression profiles of IRP2D73 and control tumors.
Elucidating the biochemical function of the 73 amino acids insert
will be important to understand the mechanism underlying the
pro-oncogenic activity of IRP2.
Materials and Methods
Cell culture
Human H1299 lung cancer cells and clones expressing wild type
IRP2 (HIRP2wt), wild type IRP1 (HIRP1wt) or the IRP2 deletion
mutants D73 (HIRP2D73), DD4 (HIRP2DD4)o rDD4/-73d
(HIRP2DD4/-73d) in a tetracycline-inducible fashion (tet-off) were
grown in Dulbecco’s modified Eagle medium (DMEM) containing
10% fetal bovine serum, 2 mM glutamine, 100 U/ml penicillin
and 0.1 mg/ml streptomycin (Wisent Inc, St-Bruno, QC). The
generation of these cell lines has been described elsewhere
[20,30,31]. Stable clones were maintained in the presence of
2 mg/ml tetracycline, 2 mg/ml puromycin and 250 mg/ml G418.
Expression of transfected proteins was induced by removal of
tetracycline from media supplemented with tetracycline-free fetal
bovine serum (Clontech).
Soft agar colony formation assay
The capacity of HIRP2wt and HIRP2D73 cells to form colonies
in soft agar was evaluated as earlier described [19].
Animal experiments
All experimental procedures were approved by the Animal Care
Committee of McGill University (Protocol 4966). Female BALB/c
(nu/nu) mice were obtained from Charles River Laboratories
(Cambridge, MA). The animals were housed in macrolone cages
(up to 5 animals/cage, 12:12 h light-dark cycle: 7 am – 7 pm;
2261uC, 6065% humidity) according to standard guidelines, and
had free access to water and food. Tumor xenografts were formed
as described in [19]. The mice were monitored three time a week
for tumor growth for up to ten weeks. All animals were euthanized
before developing any behavioral signs of disease. When indicated,
animals received tetracycline in the drinking water (2 mg/ml) 4
days before cell injection and throughout the duration of the
experiment; the solution was refreshed every second day.
Histological analysis
Tissue staining with hematoxylin and eosin, and Perl’s Prussian
blue was performed as in [19].
Preparation of cell and tumor tissue extracts
Cells were washed twice in cold PBS and lysed in a buffer
containing 20 mM Tris-Cl pH 7.4, 40 mM KCl, 1% Triton X-
100, an EDTA-free protease inhibitor cocktail (Roche) and a Halt
phosphatase inhibitor Cocktail (Thermo Scientific). Frozen tumor
tissue aliquots were suspended in the same lysis buffer and
homogenized in a 1 ml glass homogenizer. Cell debris was cleared
by centrifugation and the protein concentration was measured
with the Bradford reagent (BioRad).
Western blotting
Protein extracts (25–50 mg) were resolved by SDS-PAGE on
8%, 10% or 14% gels and the proteins were transferred onto
nitrocellulose filters (BioRad). The blots were saturated with 10%
A Role of IRP2 in Tumor Growth
PLoS ONE | www.plosone.org 9 April 2010 | Volume 5 | Issue 4 | e10163non-fat milk in PBS containing 0.1% (v/v) Tween-20 (PBS-T) and
probed with hemagglutinin (HA) (Roche), TfR1 (Zymed), ferritin
(Novus), ferroportin (raised in a rabbit against an affinity-purified
GST-fusion protein antigen containing 4 tandem copies of the C-
terminal 32 amino acid domain of mouse ferroportin), DMT1 [32]
c-MYC or VEGF (Santa Cruz), phospho-ERK1/2 or ERK1/2
(Cell Signaling), CDC14A (R&D), or b-actin (Sigma) antibodies. A
1:1000 dilution was used for all antibodies expect that for ferritin,
which was diluted 1:500. After three washes with PBS-T, the blots
were incubated with peroxidase-coupled goat anti rat IgG (Roche)
for the HA antibody, peroxidase-coupled rabbit anti-mouse IgG
(Sigma) for the TfR1, c-MYC and b-actin antibodies, peroxidase-
coupled goat anti-rabbit IgG (Sigma) for the ferroportin, ferritin,
phospho-ERK1/2 and ERK1/2 antibodies, and peroxidase-
coupled donkey anti-goat (Santa Cruz) for the VEGF antibody.
All secondary antibodies were diluted 1:5000. Peroxidase-coupled
antibodies were detected by enhanced chemiluminescence with
the Western Lightning ECL kit (Perkin Elmer). Immunoreactive
bands were quantified by densitometric scanning.
Electrophoretic mobility shift assay (EMSA)
Cytoplasmic lysates were analyzed for IRE-binding activity by
EMSA with a
32P-labeled ferritin IRE probe [33].
Metabolic labeling and immunoprecipitation
Cells were metabolically labeled with 50 mCi/ml Trans-[
35S]-
label, a mixture of 70:30
35S-methionine/cysteine (ICN). After
2 h, the cells were lysed in a buffer containing 50 mM Tris-Cl
pH 7.4, 300 mM NaCl and 1% Triton X-100. Cell debris was
cleared by centrifugation and cell lysates were subjected to
quantitative immunoprecipitation with ferritin or TfR1 antibodies
[21]. Immunoprecipitated proteins were analyzed by SDS-PAGE.
Radioactive bands were visualized by autoradiography and
quantified by phosphorimaging.
Extraction of RNA
Total RNA was isolated from frozen tumor tissue using the
RNeasy Midi kit (Qiagen). The quality of RNA was assessed by
determining the 260/280 nm absorbance ratios and by agarose gel
electrophoresis.
DNA microarray expression profiling
Total RNA (5 mg) was reverse transcribed using the Fairplay III
Microarray Labeling kit (Stratagene) and labeled with Cy3-dCTP
or Cy5-dCTP. Following clean-up using Fairplay columns
(Stratagene), labeled cDNA and universal reference (Stratagene)
were combined and hybridized to a 4644K two-color gene
expression array (Agilent Technologies). After washes according to
the manufacturer’s protocol, the array was scanned on the Agilent
DNA Microarray scanner at a resolution of 5 microns. All images
were extracted and normalized with Feature Extracter 9.5. The
microarray data are MIAME compliant and have been deposited
in the ArrayExpress database (accession number E-MEXP-2524).
Gene co-expression network inference
Pairwise similarity in gene expression vectors was expressed by
the Pearson correlation coefficient (PCC). Gene pairs that
correlated above a predefined PCC threshold were represented
in the form of an undirected unweighted network [34], where
nodes correspond to genes and links (edges) correspond to co-
expression between genes. Gene pairs with PCC $0.90 were
considered as co-expressed. To reduce the number of false positive
co-expression edges and to identify putative functionally related
gene clusters, the Markov Cluster Algorithm (MCL) method was
applied [24]. To assess significance of enrichment, only clusters
with 10 or more genes were retained. Genes identified to be
present in the same cluster were analyzed for overrepresented
Gene Ontology Biological Process (GO-BP) terms.
Quantitative real-time PCR (qPCR)
Total RNA (1 mg) was reverse transcribed using the Quantitech
Reverse Trancription Kit (Qiagen). Gene-specific primers (Table
S1) were used to perform qPCR on an MX 3005 Real-time PCR
system (Stratagene) with the Quantitech SYBR Green PCR kit
(Qiagen). The specificity of each primer set was monitored by
dissociation curve analysis. All experiments were normalized using
ribosomal protein S18 as housekeeping gene.
Statistical analysis
Results are presented as mean 6 SEM. Comparisons were
made using unpaired student’s t test. A value of P,0.05 was
considered statistically significant.
Supporting Information
Figure S1 Deletion of the 73 amino acids insert of IRP2 alters
growth properties in soft agar. (A) Schematic representation of
wild type IRP2 and the IRP2D73 deletion mutant, depicting the 4
domains of the protein, the 73 amino acids insert within domain 1,
the hinge linking domains 3 and 4, and the C-terminal HA tag. (B)
Tetracycline-inducible expression of wild type IRP2 or IRP2D73.
Extracts of parent H1299, HIRP2wt and HIRP2D73 cells, grown
for 48 h without (2) or with (+) 2 mg/ml tetracycline, were
analyzed by Western blotting with antibodies against HA (top) and
b-actin (bottom). (C) Anchorage-independent growth of the cells in
soft agar. Representative images of colonies derived from a total of
2610
4 plated cells (1006 magnification) are shown on top and
colony formation efficiency at the bottom. Media didn’t contain
tetracycline to allow expression of transfected IRP2 or IRP2D73.*
p,0,001 versus H1299 (Student’s t-test).
Found at: doi:10.1371/journal.pone.0010163.s001 (2.83 MB TIF)
Figure S2 The 73 amino acids insert of IRP2 is not sufficient to
promote tumor growth. (A) Schematic representation of wild type
IRP2 and the deletion mutants lacking domain 4, either in the
presence (IRP2DD4) or absence of the 73 amino acids insert
(IRP2DD4/273d). (B) Growth of tumor xenografts derived from
HIRP2DD4 and HIRP2DD4/273d cells (n=3 nude mice per group).
(C) Detection of mutant IRP2 expression in tumor extracts by
Western blotting with antibodies against HA and control b-actin.
(D) Mass and (E) volume of isolated tumor xenografts. Data are
expressed as mean 6 SEM. The graphs are in the same scale as
those in Figs. 1 and 2 to allow direct comparison.
Found at: doi:10.1371/journal.pone.0010163.s002 (0.70 MB TIF)
Figure S3 The low pro-oncogenic activity of IRP2D73 is not due
to reduced expression levels of this mutant in tumors. The graph
depicts the ratio of tumor volume values (derived from HIRP2wt
and HIRP2D73 cells) by the relative band intensities of HA-tagged
IRP1wt and IRP2D73 (obtained by densitometric analysis of
Western blots). Data are from three independent experiments
(n=9 mice); ** p,0.01 versus HIRP2wt (Student’s t-test). (B)
Quantification of TfR1, ferritin, ferroportin and DMT1 expres-
sion in tumor xenografts derived from HIRP2wt and HIRP2D73
cells. Western blots from three independent experiments were
quantified by densitometry. Values of protein band intensities
(mean 6SEM) were normalized to b-actin; ** p,0.01 versus
H1299 (Student’s t-test).
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Figure S4 Box plot of the normalized TFRC (TfR1) expression
values in tumor xenografts derived from parent H1299, HIRP1wt,
HIRP2wt and HIRP2D73 cells, generated by the cDNA microarray
analysis.
Found at: doi:10.1371/journal.pone.0010163.s004 (0.45 MB TIF)
Figure S5 Functional annotations of pairwise (‘‘IRP2 vs
control’’, ‘‘IRP2 vs IRP1’’ and ‘‘IRP2 vs IRP2D73’’) differentially
regulated genes in tumor xenografts derived from parent H1299,
HIRP2wt, HIRP1wt [ref. (19)] and HIRP2D73 cells.
Found at: doi:10.1371/journal.pone.0010163.s005 (0.79 MB TIF)
Figure S6 Principal component analysis. Experiments were
plotted by mapping values of 1st and 2nd principal components to
X- and Y- axis respectively. The distance of separation between
samples corresponding to ‘‘control’’ and ‘‘IRP2D73’’ tumors is
insignificant, suggesting a common signal intensity pattern.
Found at: doi:10.1371/journal.pone.0010163.s006 (0.88 MB TIF)
Table S1 Gene specific primers used for qPCR experiments.
Found at: doi:10.1371/journal.pone.0010163.s007 (0.06 MB
PDF)
Table S2 Full list of pairwise (‘‘IRP2 vs control’’, ‘‘IRP2 vs
IRP1’’ and ‘‘IRP2 vs IRP2D73’’) differentially expressed genes in
tumor xenografts derived from parent H1299, HIRP2wt, HIRP1wt
[ref. (19)] and HIRP2D73 cells.
Found at: doi:10.1371/journal.pone.0010163.s008 (0.69 MB
XLS)
Table S3 Annotation and network statistics for common
differentially expressed genes between ‘‘IRP2 vs control’’, ‘‘IRP2
vs IRP1’’ and ‘‘IRP2 vs IRP2D73’’.
Found at: doi:10.1371/journal.pone.0010163.s009 (0.15 MB
XLS)
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